CAR T-cell therapy
from Listen to The Lancet Oncology Hosted by The Lancet
Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Listen to The Lancet Oncology?
This episode is 12 minutes long.
When was this Listen to The Lancet Oncology episode published?
This episode was published on January 3, 2019.
Can I download this Listen to The Lancet Oncology episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.